Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDRX NASDAQ:DYAI NASDAQ:LITS NASDAQ:NEUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$3.07+1.3%$3.49$2.86▼$66.50$6.05M1.2322,027 shs18,428 shsDYAIDyadic International$0.80+16.7%$0.78$0.65▼$1.35$24.85M1.17597,263 shs262,868 shsLITSLite Strategy$0.80+8.0%$1.07$0.69▼$9.00$25.22M0.21513,933 shs241,548 shsNEUPNeuphoria Therapeutics$4.29-1.8%$4.92$3.64▼$21.40$23.62M0.7265,974 shs106,972 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals+1.32%-5.83%-6.97%-22.05%-94.26%DYAIDyadic International+16.70%+13.86%+10.24%-0.77%-15.33%LITSLite Strategy+8.02%+6.04%-31.58%-33.84%+80,049,900.00%NEUPNeuphoria Therapeutics-3.60%-8.14%-9.30%-6.94%-37.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$3.07+1.3%$3.49$2.86▼$66.50$6.05M1.2322,027 shs18,428 shsDYAIDyadic International$0.80+16.7%$0.78$0.65▼$1.35$24.85M1.17597,263 shs262,868 shsLITSLite Strategy$0.80+8.0%$1.07$0.69▼$9.00$25.22M0.21513,933 shs241,548 shsNEUPNeuphoria Therapeutics$4.29-1.8%$4.92$3.64▼$21.40$23.62M0.7265,974 shs106,972 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals+1.32%-5.83%-6.97%-22.05%-94.26%DYAIDyadic International+16.70%+13.86%+10.24%-0.77%-15.33%LITSLite Strategy+8.02%+6.04%-31.58%-33.84%+80,049,900.00%NEUPNeuphoria Therapeutics-3.60%-8.14%-9.30%-6.94%-37.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDRXBiodexa Pharmaceuticals 1.00SellN/AN/ADYAIDyadic International 2.33Hold$3.00276.93% UpsideLITSLite Strategy 1.00SellN/AN/ANEUPNeuphoria Therapeutics 2.00Hold$21.00389.51% UpsideCurrent Analyst Ratings BreakdownLatest BDRX, LITS, DYAI, and NEUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)6/1/2026LITSLite Strategy Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/1/2026NEUPNeuphoria Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/15/2026NEUPNeuphoria Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/13/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/29/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)3/27/2026DYAIDyadic International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDRXBiodexa Pharmaceuticals$470K13.06N/AN/A$110.30 per share0.03DYAIDyadic International$3.09M9.39N/AN/A$0.03 per share26.53LITSLite Strategy$65.30M0.42$6.67 per share0.12$4.96 per share0.16NEUPNeuphoria Therapeutics$15.65M1.48$0.15 per share28.04$10.11 per share0.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDRXBiodexa Pharmaceuticals-$8.42MN/AN/AN/AN/AN/AN/AN/AN/ADYAIDyadic International-$7.36M-$0.23N/AN/AN/A-192.40%-1,005.45%-77.64%8/12/2026 (Estimated)LITSLite Strategy-$15.94M-$1.60N/AN/AN/AN/A-90.81%-89.33%N/ANEUPNeuphoria Therapeutics-$370K-$11.06N/AN/AN/AN/A-76.93%-54.76%9/2/2026 (Estimated)Latest BDRX, LITS, DYAI, and NEUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q3 2026NEUPNeuphoria Therapeutics-$0.56-$0.09+$0.47-$0.09N/AN/A5/13/2026Q1 2026DYAIDyadic International-$0.04-$0.05-$0.01-$0.05$0.90 million$1.11 million5/13/2026Q3 2026LITSLite StrategyN/A-$0.66N/A-$0.66N/AN/A3/27/2026Q4 2025BDRXBiodexa Pharmaceuticals-$0.0066$3.5250+$3.5316-$5.35N/AN/A3/25/2026Q4 2025DYAIDyadic International-$0.03-$0.06-$0.03-$0.06$1.34 million$0.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/ALITSLite StrategyN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDRXBiodexa PharmaceuticalsN/A2.032.03DYAIDyadic International4.082.422.42LITSLite StrategyN/A11.5311.53NEUPNeuphoria TherapeuticsN/A14.3114.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDRXBiodexa Pharmaceuticals17.51%DYAIDyadic International27.95%LITSLite Strategy52.38%NEUPNeuphoria Therapeutics15.90%Insider OwnershipCompanyInsider OwnershipBDRXBiodexa Pharmaceuticals0.34%DYAIDyadic International20.90%LITSLite Strategy1.60%NEUPNeuphoria Therapeutics1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDRXBiodexa Pharmaceuticals202.00 million1.99 millionNot OptionableDYAIDyadic International736.44 million28.82 millionOptionableLITSLite Strategy10034.03 million33.48 millionN/ANEUPNeuphoria TherapeuticsN/A5.40 million5.32 millionN/ABDRX, LITS, DYAI, and NEUP HeadlinesRecent News About These CompaniesShort Interest in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Increases By 88.0%June 15 at 1:52 AM | americanbankingnews.comReviewing Neuphoria Therapeutics (NASDAQ:NEUP) and Psyence Biomedical (NASDAQ:PBM)June 6, 2026 | americanbankingnews.comHC Wainwright & Co. downgrades Neuphoria Therapeutics (NEUP)May 17, 2026 | msn.comNeuphoria Therapeutics (NEUP) price target increased by 38.22% to 13.77May 14, 2026 | msn.comHere's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn SituationFebruary 19, 2026 | uk.finance.yahoo.comNeuphoria Therapeutics (NEUP) price target decreased by 32.33% to 9.96December 22, 2025 | msn.comLeading Advisory Firms Recommend Voting FOR Lynx1's Independent NomineesDecember 8, 2025 | marketwatch.comLeading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director NomineesDecember 8, 2025 | markets.businessinsider.comLeading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director NomineesDecember 8, 2025 | globenewswire.comHC Wainwright & Co. maintains Neuphoria Therapeutics (NEUP) buy recommendationDecember 5, 2025 | msn.comNeuphoria Therapeutics price target lowered to $7 from $21 at HC WainwrightDecember 5, 2025 | msn.comNeuphoria Therapeutics responds to Lynx1’s revised indication of interestDecember 4, 2025 | msn.comNeuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and PremiumDecember 4, 2025 | finance.yahoo.comNeuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and PremiumDecember 4, 2025 | globenewswire.comLynx1 Sends Open Letter to Fellow Neuphoria ShareholdersDecember 3, 2025 | finance.yahoo.comNeuphoria Therapeutics ‘exposes false narratives’ responding to Lynx1December 1, 2025 | msn.comNeuphoria Therapeutics Inc. Responds to Allegations from Lynx1 Master Fund LP, Urges Stockholders to Support Its NomineesDecember 1, 2025 | quiverquant.comQNeuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 FictionsDecember 1, 2025 | globenewswire.comNeuphoria Therapeutics urges stockholders to vote for company nomineesNovember 24, 2025 | msn.comNeuphoria Therapeutics Inc. Sends Letter to StockholdersNovember 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDRX, LITS, DYAI, and NEUP Company DescriptionsBiodexa Pharmaceuticals NASDAQ:BDRX$3.07 +0.04 (+1.32%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$3.04 -0.02 (-0.81%) As of 05:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Dyadic International NASDAQ:DYAI$0.80 +0.11 (+16.70%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$0.76 -0.04 (-4.64%) As of 06/15/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Lite Strategy NASDAQ:LITS$0.80 +0.06 (+8.02%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$0.81 +0.01 (+0.94%) As of 06/15/2026 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Neuphoria Therapeutics NASDAQ:NEUP$4.29 -0.08 (-1.83%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$4.30 +0.01 (+0.23%) As of 06/15/2026 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
